1. Based on a survey of Omada members conducted from February 2019 through February 2021.

 

2. Methodology based on: Noble M, Chen F, Linke S, Dall TM, Napoleone J. Modeling the economic value of cardiometabolic virtual-first care programs. Am J Manag Care. 2024;30(6 Spec No.):SP430-SP436. doi:10.37765/ajmc.2024.89549

 

Omada costs savings data over time based on Markov model simulation where we have a reported clinical data point at both baseline and in the 6-12 month time period. This represents 65% of our total member population for Prevention, 62% for Diabetes, 66% for Hypertension and 72% for Diabetes + Hypertension.

Images used are not real members. Testimonials are based on members’ real experiences and individual results. We do not claim that these are typical results that members will achieve. Results may vary.

The no cost CGM sensors exclude Medicare, Medicaid, and other government payers. The Abbott FreeStyle Libre 14 day system is available to eligible participants with a valid prescription and compatible smartphone. Setup is required for continuous glucose monitoring. The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a finger stick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.